Session Details
[28-13-pm]Pharmaceutical physical chemistry/Radioactive compounds 1
Sat. Mar 28, 2026 1:10 PM - 3:10 PM JST
Sat. Mar 28, 2026 4:10 AM - 6:10 AM UTC
Sat. Mar 28, 2026 4:10 AM - 6:10 AM UTC
Room 13 (C404, Bldg. 2, Area 2 [4F])
Chair: Rie Hosoi, Shin-ichi Kondo
[28-13-pm01]Development of Sweep Imaging Microscopy for submicron particle analysis
○Tetsuo Torisu1, Mikako Takakura1, Takuto Yamaoka1, Susumu Uchiyama1 (1. Grad. Sch. Eng., The University of Osaka)
[28-13-pm02]Investigation of the Application of Mitochondria-Targeted Nanocapsules in Functional Cosmetics
○Eriko Itai1, Hiromasa Ikeda1, Kaoru Shiraki2, Yumi Kimura2, Haruna Hayase1, Keita Adachi1, Masatoshi Sekiya1, Daiki Yamakoshi1, Junko Kamimoto-Kuroki1, Yuma Yamada2 (1. KOSE Corp., 2. Fac.Pharm. Sci., Hokkaido Univ.)
[28-13-pm03S]Structural and Intermolecular Interaction Analysis of Nucleic Acid–Loaded ssPalm Lipid Nanoparticles Using Molecular Simulations
○Naoko Konami1, Koji Okuwaki1,2, Hiroki Tanaka3, Hidetaka Akita3, Kenjirou Higashi4, Takayuki Furuishi5, Etsuo Yonemochi6, Fukuzawa Kaori1 (1. Grad. Sch. Pharm. Sci., The Univ. of Osaka, 2. JSOL, 3. Grad. Sch. Pharm. Sci., Tohoku Univ., 4. Grad. Sch. Pharm. Sci., Chiba Univ., 5. Juntendo Univ., 6. International Univ. of Health and Welfare)
[28-13-pm04S]Physicochemical Characterization of Ciprofloxacin-Loaded Liposomes by Raman Spectroscopy
○Hinako Waku1, Ryouya Yamada1, Kensei Asai1, Taiki Fujimoto2, Kenjirou Higashi2, Keiji Hirota1, Tatsuo Koide3, Toshiro Fukami1 (1. Meiji Pharmaceutical Univ., 2. Grad. Sch. Pharm. Sci., Chiba Univ., 3. National Institute of Health Sciences)
[28-13-pm05S]The effect of temperature on the state of water molecules classified by Raman spectroscopy
○Takeru Ito1, Aoto Uchida1, Keiji Hirota1, Toshiro Fukami1 (1. Meiji Pharmaceutical Univ)
[28-13-pm06S]Quality control of cell culture by monitoring glucose/lactate in culture medium using Raman spectroscopy
○Hazuki Fukuta1, Haruka Uchida1, Keiji Hirota1, Toshiro Fukami1 (1. Meiji Pharmaceutical Univ)
[28-13-pm07]Investigation of amorphous formulations employing porous additives with a view toward manufacturing
○Soichiro Miura1, Ryota Makino1, Yasumasa Tashiro1 (1. Nippon Chemiphar Co.,Ltd.)
[28-13-pm08S]Development of a novel heterodimeric radioligand containing albumin binder for prostate cancer
○Shohei Tsuchihashi1, Kazuma Nakashima1, Hiroyuki Watanabe1, Masahiro Ono1 (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)
[28-13-pm09S]Development of novel 111In/177Lu-labeled radioligand for cholecystokinin 2 receptor-targeted theranostics
○Takahiro Yamamoto1, Kazuma Nakashima1, Nobuki Kazuta1, Kazuyuki Hashimoto2, Yusuke Chiba2, Shunsuke Fujino2, Yukimasa Kawauchi3, Hideya Saeki3, Naoki Takashima3, Masako Kawabata3, Hiroyuki Watanabe1, Masahiro Ono1 (1. Grad. Sch. Pharm. Sci., Kyoto Univ., 2. Japan Atomic Energy Agency, 3. Chiyoda Technol Corporation)
[28-13-pm10S]Development of novel prostate-specific membrane antigen-targeted radiopharmaceuticals containing polyethylene glycol
○Hiroki Jinda1, Kazuma Nakashima1, Hiroyuki Watanabe1, Masahiro Ono1 (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)
